U.S. Department of Defense’s Defense Health Agency RSV vaccine promotion graphic from October 2023.

It must be understood that before the Summer of 2023 there were no approved RSV vaccines: “Currently, there are no vaccines for RSV and this left many young infants and those over the age of 65 years susceptible to significant disease.”-Allison Malloy, doctor with U.S. Department of Defense’s Uniformed Services University, Bethesda, Maryland, 31JAN2023

Then suddenly in May 2023, the U.S. Food & Drug Administration (FDA) approves the first of two RSV vaccines (this is not the same as the ’emergency use’ authorization with Covid vax).  Then in July 2023, a second RSV vaccine was approved.  In August 2023, a third RSV vax specifically for pregnant women, was approved.  Arexvy was developed by the British empire’s GSK (GlaxoSmithKline).  Beyfortus/nirsevimab-alip (see CDC-IDSA warning below) was co-developed by France based Sanofi and British-Swedish AstraZeneca.  Abrysvo was developed by U.S. based Pfizer.

U.S. News & World Report, 15FEB2024: Wrong RSV Shots Given to Some Pregnant Women, Young Kids!

Medriva, 15FEB2024: RSV Vaccine Mix-up: A Wake-up Call for Better Safety & Regulation!

Rochester First, 04FEB2024: “Vaccine Adverse Event Reporting System, reported more than 150 children and pregnant women were given the wrong vaccine by doctor’s offices and pharmacies.”

It must be noted that the Vaccine Adverse Event Reporting System (VAERS) is a voluntary self-reporting system, many adverse events are not reported because the victims are either not aware of VAERS, or people are told by their healthcare providers that the adverse reaction is ‘normal’ (such as in the case of many people I know who suffered adverse reaction).

News 8 WROC New York, 04FEB2024, RSV vaccines quietly halted after mix-up:

In the last half of 2023 there were plenty of warnings about mixing up RSV, flu and Covid vaccines, and to confuse things more those warnings came from the same officials that promoted the issuing of Covid, flu and RSV vaccines at the same time.  Here are just a few;

KARE11 Minnesota, November 2023, U.S. CDC reports mix-up involving vaccines for babies and adults:

The Hill, October 2023: Insurance, distribution, confusing packaging, and funding are causing problems with the U.S. CDC’s new recommendation to ‘mix-n-max’ vaccine brands!

The U.S. CDC’s own Infectious Diseases Society of America (IDSA), September 2023: “Unlike the other influenza, COVID-19 and RSV vaccines available during this fall/winter season, nirsevimab is a monoclonal antibody, classified as a drug by FDA. It is ‘vaccine-like’ in that it is an ‘immunization’ recommended by CDC’s ACIP and covered under the Vaccines for Children program. However, it is ‘drug-like’ in that potential adverse events occurring after nirsevimab administration should be reported to FDA (through MedWatch or the FDA Adverse Event Reporting System), not the Vaccine Adverse Event Reporting System. (If children receive any non-nirsevimab vaccine simultaneously with nirsevimab, any potential subsequent adverse events should be reported both to MedWatch/FAERS and VAERS.) CDC’s Immunization Safety Office and FDA’s Center for Drug Evaluation and Research are working together to ensure continuous and robust safety monitoring of nirsevimab.”

University of Nebraska Medical Center, September 2023: “…three vaccines this fall — a COVID booster, the flu shot, and the new respiratory syncytial virus (RSV) vaccine…  …there are no data on giving this trio of vaccines at the same time, most experts advise a different strategy.”

Public Health Ontario (Canada), September 2023:  “There are currently no data available regarding the co-administration of the RSV vaccine with COVID-19 vaccines or for the co-administration of the RSV, COVID-19 and influenza vaccines.  Therefore, the potential for immune impacts and AEs [Adverse Events] attributable to co-administration in these circumstances is unknown.” 

The following is a boring, four and a half hours long, U.S. CDC Advisory Committee on Immunization Practices (ACIP) meeting, from June 2023, discussing the economical possibilities of issuing multiple vaccines at the same time, which included flu, Covid and new RSV vaccines.  It should be noted that the pharmaceutical manufacturers had a large role in the presentation:

Vaccine Fail: TAXPAYER FUNDED STUDY SAYS mRNA BOOSTER DOES-NOT PREVENT DEATH, but it DOES INCREASE INFECTIONS!

Pandēmus Totalitarian: GAVI & U.S. ARMY BEHIND NEW MANDATORY “ROUTINE” RTS,S-VAX PROGRAM IN AFRICA!